In summary, many studies have found that high LGR5 expression is associated with chemoresistance in breast, cervical, colorectal, hepatic, gastric and ovarian cancer to a wide range of chemotherapy drugs including carboplatin, cisplatin, paclitaxel oxaliplatin, 5-FU and doxorubicin. The gene discussed is LGR5; the disease is ovarian cancer.